講演情報
[AS1-2]Do probiotics and prebiotics have value in improving the treatment outcome of CRC?
Ji Won PARK (Department of Surgery, Seoul National University Hospital and Seoul National University College of Medicine, Korea)
The relationship between the microbiome and colorectal cancer（CRC）is significant, with the microbiome playing a crucial role in CRC outcomes. Probiotics and prebiotics have shown potential in improving CRC treatment outcomes. Probiotics, such as Lactobacillus and Bifidobacterium, and prebiotics, which are substrates utilized by host microorganisms, can positively impact CRC treatment by modulating the gut microbiota.
The gut microbiota also influences anastomotic healing in CRC surgery by modulating local wound inflammation and repair processes. Specific microorganisms, such as Parabacteroides goldsteinii, have anti-inflammatory effects and improve gut barrier restoration and wound healing. Additionally, the gut microbiome affects the symptoms and severity of Low Anterior Resection Syndrome（LARS）, a common complication after rectal cancer surgery.
Prognostic gut microbiota, including Prevotella and Fusobacterium nucleatum, serve as biomarkers for CRC prognosis. Higher abundance of Prevotella is associated with better prognosis, while certain species like Fusobacterium nucleatum are linked to poor prognosis. Personalized therapy targeting the microbiome and metabolome shows promise in improving LARS symptoms and overall CRC treatment outcomes.
In conclusion, the integration of probiotics and prebiotics into CRC treatment regimens, along with personalized microbiome modulation, holds potential for enhancing treatment outcomes and patient quality of life.
The gut microbiota also influences anastomotic healing in CRC surgery by modulating local wound inflammation and repair processes. Specific microorganisms, such as Parabacteroides goldsteinii, have anti-inflammatory effects and improve gut barrier restoration and wound healing. Additionally, the gut microbiome affects the symptoms and severity of Low Anterior Resection Syndrome（LARS）, a common complication after rectal cancer surgery.
Prognostic gut microbiota, including Prevotella and Fusobacterium nucleatum, serve as biomarkers for CRC prognosis. Higher abundance of Prevotella is associated with better prognosis, while certain species like Fusobacterium nucleatum are linked to poor prognosis. Personalized therapy targeting the microbiome and metabolome shows promise in improving LARS symptoms and overall CRC treatment outcomes.
In conclusion, the integration of probiotics and prebiotics into CRC treatment regimens, along with personalized microbiome modulation, holds potential for enhancing treatment outcomes and patient quality of life.